97 related articles for article (PubMed ID: 23330344)
1. Chronic lymphocytic leukemia with del(17p13.1): a distinct clinical subtype requiring novel treatment approaches.
Stephens DM; Byrd JC
Oncology (Williston Park); 2012 Nov; 26(11):1044-54. PubMed ID: 23330344
[TBL] [Abstract][Full Text] [Related]
2. Novel agents and strategies for treatment of p53-defective chronic lymphocytic leukemia.
Grever MR; Lucas DM; Johnson AJ; Byrd JC
Best Pract Res Clin Haematol; 2007 Sep; 20(3):545-56. PubMed ID: 17707839
[TBL] [Abstract][Full Text] [Related]
3. An unusual presentation of a chronic lymphocytic leukemia patient with 17p deletion after reduced-intensity transplantation: Richter syndrome and concomitant graft-versus-host disease--case report.
Salihoglu A; Ozbalak M; Keskin D; Tecimer T; Soysal T; Ferhanoglu B
Transplant Proc; 2013 Sep; 45(7):2845-8. PubMed ID: 23747187
[TBL] [Abstract][Full Text] [Related]
4. 17p deletion in chronic lymphocytic leukemia: risk stratification and therapeutic approach.
Schnaiter A; Stilgenbauer S
Hematol Oncol Clin North Am; 2013 Apr; 27(2):289-301. PubMed ID: 23561474
[TBL] [Abstract][Full Text] [Related]
5. A new hope: novel therapeutic approaches to treatment of chronic lymphocytic leukaemia with defects in TP53.
Shindiapina P; Brown JR; Danilov AV
Br J Haematol; 2014 Oct; 167(2):149-61. PubMed ID: 25040077
[TBL] [Abstract][Full Text] [Related]
6. [Molecular cytogenetic characteristics of chronic lymphocytic leukemia].
Xu W; Li JY; Pan JL; Qiu HR; Shen YF; Xiao B; Chen LJ; Wu YF; Sheng RL; Xue YQ
Zhonghua Zhong Liu Za Zhi; 2006 May; 28(5):349-52. PubMed ID: 17044998
[TBL] [Abstract][Full Text] [Related]
7. Select high-risk genetic features predict earlier progression following chemoimmunotherapy with fludarabine and rituximab in chronic lymphocytic leukemia: justification for risk-adapted therapy.
Byrd JC; Gribben JG; Peterson BL; Grever MR; Lozanski G; Lucas DM; Lampson B; Larson RA; Caligiuri MA; Heerema NA
J Clin Oncol; 2006 Jan; 24(3):437-43. PubMed ID: 16344317
[TBL] [Abstract][Full Text] [Related]
8. Immunotherapeutic approaches have the potential to brighten the future not only for patients with del(17p13.1), but for all CLL patients.
McClanahan F; Gribben JG
Oncology (Williston Park); 2012 Nov; 26(11):1055, 1058. PubMed ID: 23330345
[No Abstract] [Full Text] [Related]
9. Activity of cladribine combined with cyclophosphamide in frontline therapy for chronic lymphocytic leukemia with 17p13.1/TP53 deletion: report from the Polish Adult Leukemia Group.
Robak T; Blonski JZ; Wawrzyniak E; Gora-Tybor J; Palacz A; Dmoszynska A; Konopka L; Warzocha K; Jamroziak K
Cancer; 2009 Jan; 115(1):94-100. PubMed ID: 19025975
[TBL] [Abstract][Full Text] [Related]
10. Impact of trisomy 12, del(13q), del(17p), and del(11q) on the immunophenotype, DNA ploidy status, and proliferative rate of leukemic B-cells in chronic lymphocytic leukemia.
Quijano S; López A; Rasillo A; Sayagués JM; Barrena S; Sánchez ML; Teodosio C; Giraldo P; Giralt M; Pérez MC; Romero M; Perdiguer L; Orfao A
Cytometry B Clin Cytom; 2008 May; 74(3):139-49. PubMed ID: 18061951
[TBL] [Abstract][Full Text] [Related]
11. In vitro activity of 20 agents in different prognostic subgroups of chronic lymphocytic leukemia--rolipram and prednisolone active in cells from patients with poor prognosis.
Lindhagen E; Norberg M; Kanduri M; Tobin G; Säisänen L; Aberg M; Gustafsson MG; Sundström C; Rosenquist R; Aleskog A
Eur J Haematol; 2009 Jul; 83(1):22-34. PubMed ID: 19245531
[TBL] [Abstract][Full Text] [Related]
12. Late appearance of the 11q22.3-23.1 deletion involving the ATM locus in B-cell chronic lymphocytic leukemia and related disorders. Clinico-biological significance.
Cuneo A; Bigoni R; Rigolin GM; Roberti MG; Bardi A; Cavazzini F; Milani R; Minotto C; Tieghi A; Della Porta M; Agostini P; Tammiso E; Negrini M; Castoldi G
Haematologica; 2002 Jan; 87(1):44-51. PubMed ID: 11801464
[TBL] [Abstract][Full Text] [Related]
13. Interphase cytogenetic abnormalities in chronic lymphocytic leukemia may predict response to rituximab.
Byrd JC; Smith L; Hackbarth ML; Flinn IW; Young D; Proffitt JH; Heerema NA
Cancer Res; 2003 Jan; 63(1):36-8. PubMed ID: 12517774
[TBL] [Abstract][Full Text] [Related]
14. Allogeneic hematopoietic stem-cell transplantation for chronic lymphocytic leukemia with 17p deletion: a retrospective European Group for Blood and Marrow Transplantation analysis.
Schetelig J; van Biezen A; Brand R; Caballero D; Martino R; Itala M; García-Marco JA; Volin L; Schmitz N; Schwerdtfeger R; Ganser A; Onida F; Mohr B; Stilgenbauer S; Bornhäuser M; de Witte T; Dreger P
J Clin Oncol; 2008 Nov; 26(31):5094-100. PubMed ID: 18711173
[TBL] [Abstract][Full Text] [Related]
15. Prognosis and therapy of chronic lymphocytic leukemia and small lymphocytic lymphoma.
Sun C; Wiestner A
Cancer Treat Res; 2015; 165():147-75. PubMed ID: 25655609
[TBL] [Abstract][Full Text] [Related]
16. Chronic lymphocytic leukemia: 2013 update on diagnosis, risk stratification and treatment.
Hallek M
Am J Hematol; 2013 Sep; 88(9):803-16. PubMed ID: 23720127
[TBL] [Abstract][Full Text] [Related]
17. Biological and clinical characterization of recurrent 14q deletions in CLL and other mature B-cell neoplasms.
Reindl L; Bacher U; Dicker F; Alpermann T; Kern W; Schnittger S; Haferlach T; Haferlach C
Br J Haematol; 2010 Oct; 151(1):25-36. PubMed ID: 20649559
[TBL] [Abstract][Full Text] [Related]
18. Cytogenetic and molecular cytogenetic analysis of B cell chronic lymphocytic leukemia: specific chromosome aberrations identify prognostic subgroups of patients and point to loci of candidate genes.
Döhner H; Stilgenbauer S; Fischer K; Bentz M; Lichter P
Leukemia; 1997 Apr; 11 Suppl 2():S19-24. PubMed ID: 9178833
[TBL] [Abstract][Full Text] [Related]
19. Clinical and therapeutic implications of the mutational status of IgVH in patients with chronic lymphocytic leukemia.
Kharfan-Dabaja MA; Chavez JC; Khorfan KA; Pinilla-Ibarz J
Cancer; 2008 Sep; 113(5):897-906. PubMed ID: 18618518
[TBL] [Abstract][Full Text] [Related]
20. The role of prognostic factors in assessing 'high-risk' subgroups of patients with chronic lymphocytic leukemia.
Kay NE; O'Brien SM; Pettitt AR; Stilgenbauer S
Leukemia; 2007 Sep; 21(9):1885-91. PubMed ID: 17568813
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
